Initial renal function and type of chemotherapy: impact on treatment efficacy in patients with chronic lymphocytic leukemia
https://doi.org/10.17650/1818-8346-2015-1-24-28
Abstract
The paper presents an assessment of treatment efficacy in chronic lymphocytic leukemia CLL patients according to chemotherapy type and initial renal function. The high efficacy of chemotherapy with fludarabine in CLL patients with or without renal failure at diagnosis was revealed. However, regardless of chemotherapy type initial treatment response was worse in patients with renal failure.
About the Authors
A. K. Nikitina
Irkutsk State Medical University; 1 Krasnogo Vosstaniya St., Irkutsk, 664003, Russia
Russian Federation
Russian Federation
N. O. Saraeva
Irkutsk State Medical University; 1 Krasnogo Vosstaniya St., Irkutsk, 664003, Russia
Russian Federation
Russian Federation
References
1. Волкова М. А. Клиническая гематология: руководство для врачей. 2-е издание. М.: Медицина, 2007. 1120 с. [Volkova M. A. Clinical hematology: physicians guide. 2nd edition. M.: Medicine, 2007. 1120 pp. (In Russ.)].
2. Никитин Е. А. Дифференцированная терапия хронического лимфолейкоза. Дис. ... д-ра мед. наук. М., 2014. [Nikitin E. A. Differentiated therapy of chronic lymphocytic leukemia. Dissert. D. Sci. M., 2014. (In Russ.)].
3. Воробьев А. И. Руководство по гематологии. 4-е издание. М.: Ньюдиамед, 2007. 1275 с. [Vorobyev A. I. Manual of Hematology. 4th Edition. M.: Newdiamed, 2007. 1275 pp. (In Russ.)].
4. Стадник Е. А., Никитин Е. А., Алексеева Ю. А. и др. Современная лекарственная терапия и прогностические факторы при хроническом лимфолейкозе. Обзор литературы и собственные данные. Бюллетень сибирской медицины 2008;7(Прил. 3):41–52. [Stadnik E. A., Nikitin E. A., Alekseeva Yu. A. et al. Current drug therapy and prognostic factors in chronic lymphocytic leukemia. Own data and literature review. Byulleten sibirskoy mediciny = Bulletin of the Siberian Medicine 2008;7(Suppl. 3):41–52. (In Russ.)].
5. Badoux X. C., Keating M. J., Wang X. et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011;117(11):3016–24.
6. Catovsky D., Richards S., Matutes E. et al. UK National Cancer Research Institute (NCRI); Haematological Oncology Clinical Studies Group; NCRI Chronic Lyphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370(9583):230–9.
7. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под рук. проф. И. В. Поддубной, проф. В. Г. Савченко. М.: Медиа Медика, 2013. С. 104. [Russian clinical guidelines for diagnosis and treatment of lymphoproliferative disoders. Ed.: prof. Poddubnaya I. V., prof. Savchenko V. G. M.: Media Medica, 2013. 104 pp. (In Russ.)].
8. Woyach J. A., Ruppert A. S., Peterson B. et al. Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies. ASH Annual Meeting Abstracts 2011;118:289.
9. Foon K. A., Boyiadzis M., Land S. R. et al. Chemoimmunotherapy with low dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27(4):498–503.
10. Hillmen P., Gribben J., Follows G. et al. Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): final response analysis of an open-label phase II study. Blood 2010;116:307.
11. Hallek M., Fischer K., Fingerle- Rowson G. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164–74.
12. Бялик Т. Е., Гривцова Л. Ю., Карселадзе А. И. и др. Некоторые прогностические факторы при современной терапии хронического лимфолейкоза. Современная онкология 2007;8(4):1–6. [Byalik T. E., Grivtsova L. Yu., Karseladze A. I. et al. Some of prognostic factors in therapy of chronic lymphocytic leukemia. Sovremennaya oncologiya = The Modern Oncology 2007;8 (4):1–6. (In Russ.)].
13. Загоскина Т. П. Сравнительная оценка эффективности флударабинсодержащих режимов и иммунохимиотерапии при хроническом лимфолейкозе. Терапевтический архив 2010;82(1):35–9. [Zagoskina T. P. Comparative efficacy of fludarabine-containing regimens and immunochemotherapy in chronic lymphocytic leukemia. Terapevticheskiy archive = Therapeutic Archives 2010;82(1):35–9. (In Russ.)].
14. Hallek M., Fingerle-Rowson G., Fink A. M. et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C) and rituximab (R)(FCR) versus fludarabine and cyclophosphamide (FC) impruves responses rates and progression-free survival (PFS) of previously untreated patients with advanced hronic lymphocytic leukemia. Blood 2008;112:325.
15. Ворожейкина Е. Г., Савченко В. Г., Варшавский В. А. и др. Поражение почек при гемобластозах. Терапевтический архив 2005;7:16–22. [Vorozheykina E. G., Savchenko V. G., Varshavskiy V. A. et al. Kidney involvement in hematological malignancies. Terapevticheskiy archive = Therapeutic Archives 2005;7:16–22. (In Russ.)].
16. Cheson B. P., Bennett J. M., Grever M. et al. National Cancer Institute-sponsoredWorking Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87(12):4990–7.
17. Hallek M., Cheson B. D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446–56.
18. Levey A. S., Stevens L. A., Schmid C. H. et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604–12.
19. Лебедева О. Л. Особенности клинического течения и терапии заболеваний почек атеросклеротического генеза у больных пожилого и старческого возраста. Дис. ... канд. мед. наук. Воронеж, 2004. [Lebedeva O. L. Clinical course and treatment of atherosclerotic kidney disease in elderly patients. Dissert. PhD. Voronezh, 2004. (In Russ.)].
20. Бессмельцев С. С., Абдулкадыров К. М. Поражение почек у больных хроническим лимфолейкозом. Урология и нефрология 1999;2:32–4. [Bessmeltsev S. S., Abdulkadyrov K. M. Kidney involvement in patients with chronic lymphocytic leukemia. Urologiya i nefrologiya = Urology and Nephrology 1999;2:32–4. (In Russ.)].
21. Денисова Т. П., Малинова Л. И. Клиническая геронтология: Избранные лекции. М., 2008. 256 с. [Denisova T. P., Malinova L. I. Clinical Gerontology: Selected Lectures. M., 2008. 256 pp. (In Russ.)]
22. Фомин В. В. Ишемическая болезнь почек: Клиническая картина, патогенез, тактика ведения. Дис. ... канд. мед. наук. М., 2008.[Fomin V. V. Ischemic renal disease: clinical picture, pathogenesis, management. Dissert. PhD. M., 2008 (In Russ.)].
23. Мухин Н. А., Хасабов Н. Н. Паранео-пластические нефропатии. Руководство для врачей под ред. И. Е. Тареевой. М.: Медицина, 2000. С. 540–545. [Mukhin N. A., Khasabov . N. Paraneoplastic nephropathy. Physicians Guide. Ed.: Tareeva I. E. M.: Medicine, 2000. Pp. 540–545. (In Russ.)].
24. Захарова Е. В. ANCA-ассоциированные криоглобулинемические васкулиты – диагностика и лечение. Нефрология и диализ 2005;1:78–92. [Zakharova E. V. ANCA-associated cryoglobulinemic vasculitis – diagnosis and treatment. Nefrologiya i dializ = Nephrology and Dialysis 2005;1:78–92. (In Russ.)].
25. Рехтина И. Г., Бирюкова Л. С. Поражение почек при моноклональной иммуноглобулинопатии. Нефрология и диализ 2005;7(4):422–4. [Rekhtina I. G., Biryukova L. S. Kidney involvement in monoclonal immunoglobulinopaties. Nefrologiya i dializ = Nephrology and Dialysis 2005;7(4):422–4. (In Russ.)].
26. Ronco P. M. Paraneoplastic glomerulopathies: New insights into an old entity. Kidney Int 1999;56:355–77.
Review
For citations:
Nikitina A.K., Saraeva N.O. Initial renal function and type of chemotherapy: impact on treatment efficacy in patients with chronic lymphocytic leukemia. Oncohematology. 2015;10(1):24-28. (In Russ.) https://doi.org/10.17650/1818-8346-2015-1-24-28
Views:
9894
Email this article 